当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2019年, 第19卷, 第4期, 第241-243,320页
标题:
胰腺癌的靶向治疗药物研究进展
DOI:
10.5428/pcar20190401
作者:
1. 史亚敏1(1.福建中医药大学药学院药剂学教研室 福州 350108 1576671627@qq.com)
2. 鲁悦2(2.上海维洱实验室 上海 201712 )
3. 武鑫2(2.上海维洱实验室 上海 201712 )
4. 陈建明1(1.福建中医药大学药学院药剂学教研室 福州 350108 yjcjm@163.com)
摘要:
摘要  胰腺癌是一种恶性消化系统肿瘤,发病率和死亡率几乎一致。现有的治疗方法主要为手术切除和联合放、化疗,但存在一定的局限性。与传统的治疗方式相比,靶向治疗药物具有精准到达肿瘤细胞或组织,抑制或杀死肿瘤细胞的优点。本文从血管靶向药物、细胞靶向药物、免疫靶向药物3个方面,对近年来胰腺癌靶向治疗药物的研究进展作一综述。
欢迎阅读《药学服务与研究》!您是该文第 127 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 史亚敏1,鲁悦2,武鑫2,陈建明1. 胰腺癌的靶向治疗药物研究进展[J]. 药学服务与研究. 2019; 19(4): 241-243,320.
英文著录格式 SHI Yamin1,LU Yue2,WU Xin2,CHEN Jianming1. Research advances in targeted therapeutic drugs of pancreatic cancer[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(4): 241-243,320.
参考文献:
1. 李慧超,王宁,郑荣寿,等.中国2010年胰腺癌发病和死亡分析[J].中国肿瘤,2015,24(3):163-169.
2. 白燕南,严茂林.胰腺癌综合诊治指南(2018版)外科相关部分解读[J].中国普外基础与临床杂志,2018,25(6):669-672.
3. 张东梅,卿晨.血管内皮生长因子家族及其受体与肿瘤血管新生[J].医学综述,2017,23(3):417-420,427.
4. Itatani Y,Kawada K,Yamamoto T,et al.Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway[J].Int J Mol Sci,2018,19(4):1232.
5. Tai C J,Huang M T,Wu C H,et al.Combination of two targeted medications (bevacizumab plus cetuximab) improve the therapeutic response of pancreatic carcinoma[J].Medicine(Baltimore),2016,95(15):e3259.
6. Tai C J,Wang H,Wang C K,et al.Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts[J].Clin Exp Med,2017,17(2):141-150.
7. Noorani M,Azarpira N,Karimian K,et al.Erlotinib-loaded albumin nanoparticles:a novel injectable form of erlotinib and its in vivo efficacy against pancreatic adenocarcinoma ASPC-1 and PANC-1 cell lines[J].Int J Pharm,2017,531(1):299-305.
8. 贾丛伟,孙洋,张婷婷,等.miR-125a-5p对胰腺癌细胞增殖、凋亡和细胞周期的影响[J].中国医学科学院学报,2016,38(4):415-421.
9. 李峄清,朱海峰,王璐.吉西他滨联合清蛋白结合型紫杉醇治疗胰腺癌的临床疗效及安全性[J].临床合理用药,2017,10(5C):33-34.
10. Von Hoff D D,Ervin T,Arena F P,et al.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J].N Engl J Med,2013,369(18):1691-1703.
11. Horiuchi T,Uwagawa T,Shirai Y,et al.New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer[J].J Surg Res,2016,206(1):1-8.
12. 朱凌曦,安华章.PD-L1表达调控机制及其对抗肿瘤免疫反应的影响[J].中国肿瘤生物治疗杂志,2017,24(4):335-340.
13. Foley K,Kim V,Jaffee E,et al.Current progress in immunotherapy for pancreatic cancer[J].Cancer Lett,2016,381(1):244-251.
14. Patnaik A,Kang S P,Rasco D,et al.Phase Ⅰ study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors[J].Clin Cancer Res,2015,21(19):4286-4293.
15. Long G V,Atkinson V,Lo S,et al.Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases:a multicentre randomised phase 2 study[J].Lancet Oncol,2018,19(5):672-681.
16. Royal R E,Levy C,Turner K,et al.Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma[J].J Immunother,2010,33(8):828-833.
17. Mass-Vall s D,Jauset T,Serrano E,et al.Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma[J].Cancer Res,2015,75(8):1675-1681.
18. Allen E,Jabouille A,Rivera L B,et al.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation[J].Sci Transl Med,2017,9(385):eaak9679.
19. YE Zhenlong,QIAN Qiming,JIN Huajun,et al.Cancer vaccine:learning lessons from immune checkpoint inhibitors[J].J Cancer,2018,9(2):263-268.
20. Yokoyama S,Kitamoto S,Higashi M,et al.Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice[J].PLoS One,2014,9(4):e93760.
21. Shindo Y,Hazama S,Maeda Y,et al.Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer[J].J Transl Med,2014,12:175.
22. Middleton G,Silcocks P,Cox T,et al.Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac):an open-label,randomised,phase 3 trial[J].Lancet Oncol,2014,15(8):829-840.